These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38577712)

  • 1. Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate.
    Kaplan S; Dragut CF; Ghimpeteanu A
    Curr Med Res Opin; 2024 May; 40(5):821-825. PubMed ID: 38577712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy and fetal outcomes following maternal exposure to glatiramer acetate in all three trimesters of pregnancy.
    Kaplan S; Zeygarnik M; Stern T; Hellwig K
    Eur J Neurol; 2023 Dec; 30(12):3890-3895. PubMed ID: 37565380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate during early pregnancy: A prospective cohort study.
    Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding.
    Kaplan S; Zeygarnik M; Stern T
    Drug Saf; 2022 Apr; 45(4):345-357. PubMed ID: 35297004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.
    Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Piscolla E; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; La Mantia L; Mancardi G; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP
    BMC Neurol; 2012 Oct; 12():124. PubMed ID: 23088447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.
    Pecori C; Giannini M; Portaccio E; Ghezzi A; Hakiki B; Pastò L; Razzolini L; Sturchio A; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; Mancardi GL; Solaro C; Totaro R; Tola MR; De Luca G; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP;
    BMC Neurol; 2014 May; 14():114. PubMed ID: 24884599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases.
    Meserve J; Luo J; Zhu W; Veeravalli N; Bandoli G; Chambers CD; Singh AG; Boland BS; Sandborn WJ; Mahadevan U; Singh S
    Gastroenterology; 2021 Jul; 161(1):107-115.e3. PubMed ID: 33744307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G; Galazka A; Schick R; Leist T; Comi G; Montalban X; Damian D; Dangond F; Cook S
    Drug Saf; 2020 Jul; 43(7):635-643. PubMed ID: 32447743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population.
    Andersen JB; Wandall-Holm MF; Magyari M
    Mult Scler Relat Disord; 2022 Mar; 59():103529. PubMed ID: 35091367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpregnancy interval and adverse pregnancy outcomes among pregnancies following miscarriages or induced abortions in Norway (2008-2016): A cohort study.
    Tessema GA; Håberg SE; Pereira G; Regan AK; Dunne J; Magnus MC
    PLoS Med; 2022 Nov; 19(11):e1004129. PubMed ID: 36413512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy.
    Eck LK; Jensen TB; Mastrogiannis D; Torp-Pedersen A; Askaa B; Nielsen TK; Poulsen HE; Jimenez-Solem E; Andersen JT
    Obstet Gynecol; 2017 Apr; 129(4):707-714. PubMed ID: 28277353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure to golimumab during pregnancy: Results from the Company's global safety database.
    Otero-Lobato M; Adeyemo A; Higley M; Lomax KG; Geldhof A; Esslinger S
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1240. PubMed ID: 38970433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
    MacDonald SC; McElrath TF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    Hellwig K; Geissbuehler Y; Sabidó M; Popescu C; Adamo A; Klinger J; Ornoy A; Huppke P;
    J Neurol; 2020 Jun; 267(6):1715-1723. PubMed ID: 32100126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dutch Pregnancy Drug Register: Suitable to Study Paternal Drug Exposures?
    van der Mijle AE; Woestenberg PJ; Kosse LJ; van Puijenbroek EP
    Int J Environ Res Public Health; 2023 Nov; 20(23):. PubMed ID: 38063537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women.
    Liu J; Zhao Y; Song Y; Zhang W; Bian X; Yang J; Liu D; Zeng X; Zhang F
    J Matern Fetal Neonatal Med; 2012 Mar; 25(3):261-6. PubMed ID: 21504337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mothers with long QT syndrome are at increased risk for fetal death: findings from a multicenter international study.
    Cuneo BF; Kaizer AM; Clur SA; Swan H; Herberg U; Winbo A; Rydberg A; Haugaa K; Etheridge S; Ackerman MJ; Dagradi F; Killen SAS; Wacker-Gussmann A; Benson DW; Wilde AAM; Pan Z; Lam A; Spazzolini C; Horigome H; Schwartz PJ;
    Am J Obstet Gynecol; 2020 Mar; 222(3):263.e1-263.e11. PubMed ID: 31520628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update.
    Brin MF; Kirby RS; Slavotinek A; Adams AM; Parker L; Ukah A; Radulian L; Elmore MRP; Yedigarova L; Yushmanova I
    Neurology; 2023 Jul; 101(2):e103-e113. PubMed ID: 37137724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.
    Lu E; Zhu F; Zhao Y; van der Kop M; Synnes A; Dahlgren L; Sadovnick AD; Traboulsee A; Tremlett H
    CNS Drugs; 2014 May; 28(5):475-82. PubMed ID: 24643915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.